Pear Therapeutics Launches Digital Insomnia Telehealth App

The pandemic has led to a rise in sleep problems. Somryst seeks to address chronic insomnia by training the body and brain to fall asleep faster and stay asleep longer.

woman at home bedroom lying in bed late at night trying to sleep

Pear Therapeutics, Inc. announced on 18 November it launched its prescription digital therapeutics dubbed Somryst aimed to help patients 22 and older with chronic insomnia.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Digital Technologies

Anglonordic 25: Pictura Bio’s One-Minute Pathogen-Identifying Diagnostic Test

 

“Infectious disease should be treated in the community, not in hospitals,” Alex Batchelor, Pictura Bio CEO, told Medtech Insight at the Anglonordic Life Science Conference on 3 April in London.

Birmingham City University Develops New Defense Mechanism Against Cyberattacks On AI Systems

 

AI systems used in healthcare are vulnerable to adversarial cyberattacks, which are a growing concern, said Atif Azad, a professor of AI at Birmingham City University. Azad’s research group has developed a method that trains AI to become more resilient to cyber threats through the use of random image adjustments.

LSI 2025: Egg Medical Builds ‘Nests’ Around Interventional Cardiologists To Protect Against Scatter Radiation

 
• By 

Egg Medical is ramping up efforts to expand international sales of its EggNest scatter radiation protection system to shield X-ray procedure room staff without disrupting workflow. Medtech Insight sat down with Bob Wilson, Egg Medical’s CEO, to discuss the various EggNest systems, marketing opportunities and the competitive landscape.

Shuren Expects Longer CDRH Review Times

 
• By 

The FDA staff cuts will probably mean longer device review times at least in the short term, speakers said at a recent webinar. But innovations like AI and third-party review could offer some hope, even as tariffs create a new set of problems.

More from Medtech Insight

OneCell Diagnostics’ Mohan Uttarwar Discusses How AI Helps To Predict Cancer’s Next Move

 
• By 

In an interview with Medtech Insight, Uttarwar breaks down how OneCell’s proprietary single-cell biopsy platform is rewriting the rules of cancer diagnostics – not just identifying cancer at the cellular level but predicting its potential return with unprecedented accuracy. He also shares how the company’s approach leverages single-cell biopsy technology and machine learning to spot signs of cancer’s return before it manifests clinically.

Secretary Kennedy’s FDA Visit Included CDRH Stop, Speech Warning Of ‘Agency Capture’

 
• By 

HHS Secretary Robert F. Kennedy Jr. urged FDA staff to resist the “deep state” and “crony capitalism,” and focus on improving the health of America’s children. “You're not here to take orders,” he said and urged FDA staff to speak up if they see wrongdoing.

Execs On The Move: 31 March to 4 April 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.